GSK_ Annual_Report_2021-22

GSK plc at a glance 3,500+ People work in our offices, manufacturing facility and sales teams across India #1 In Vaccines self-pay market* #1 In Dermatology segment* Key facts | India *Source: IQVIA MAT March 2022 Our priorities | India Innovation At GSK, innovation is embedded in our pathbreaking products. We endeavour to launch relevant products from our parent company’s promising pipeline. Page 08 Performance We deliver growth by investing effectively in our business, developing our people and executing competitively. Page 10 Trust Our people help deliver on our ambition for patients, address select national health priorities and widen access to medicines to create value for our stakeholders and society at large. Page 12 About our new logo The new logo reflects our new purpose and growth ambitions. It combines science, technology and talent, whilst also retaining key elements of our heritage. The name and distinctive orange, both prominent features of our identity, remain an important part of the updated brand. Our purpose We unite science, technology and talent to get ahead of disease together For health impact + shareholder returns + thriving people OUR STRATEGY We prevent and treat disease with vaccines, specialty and general medicines. We focus on science of the immune system, human genetics, and advanced technologies investing in 4 core therapeutic areas and future opportunities to impact health at scale. We operate responsibly for all our stakeholders by prioritising Innovation, Performance and Trust. OUR CULTURE Ambitious for patients To deliver what matters better and faster Accountable for impact With clear ownership and support to succeed Do the right thing With integrity and care because people count on us GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22